crossover randomized trial
NCT01562678
Liraglutide in Obesity and Diabetes: Identification of CNS Targets Using fMRI
Design
Conduct and analysis
Arms
| Arm | Treatment | Background | Randomized | Analyzed | Completed treatment |
|---|---|---|---|---|---|
| A1 | Placebo Placebo | lifestyle or metformin; lifestyle: not reported | 28 | 18 | |
| A2 | Liraglutide 1.8 mg subcutaneous once daily Liraglutide 1.8 mg | lifestyle or metformin; lifestyle: not reported | 28 | 18 |
Baseline characteristics
As printed in the trial reports or registry, per arm or for the whole trial.
| Characteristic | Statistic | Placebo A1 | Liraglutide 1.8 mg subcutaneous once daily A2 | Whole trial ALL |
|---|---|---|---|---|
| age | mean (years) | 52.5 | ||
| age | sd (years) | 10.5 | ||
| bmi | mean (kg/m2) | 31.2 | 31.9 | |
| bmi | se (kg/m2) | 1.7 | 1.7 | |
| female | n | 12 | ||
| waist | mean (cm) | 105.1 | 106.8 | |
| waist | se (cm) | 3.5 | 3.5 | |
| weight | mean (kg) | 93.4 | 94.7 | |
| weight | se (kg) | 4.8 | 4.7 |
Results
12 adjudicated result lines, grouped by outcome. Open an outcome to see its values.
HbA1c change (2 lines; O01)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| 2.43 | A1 | final | 6.7 percent | 0.2 | 18 | not stated; completers; R0022856:Table 2 | |
| 2.43 | A2 | final | 6.7 percent | 0.2 | 18 | not stated; completers; R0022856:Table 2 |
Body weight change in kilograms (diabetes) (2 lines; O02)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| 2.43 | A1 | final | 91.1 kg | 1.0 | 18 | not stated; completers; R0022856:Table 2 | |
| 2.43 | A2 | final | 91.0 kg | 1.0 | 18 | not stated; completers; R0022856:Table 2 |
All cause mortality (2 lines; O20)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| A1 | events | 0 / 28 | not stated; safety; registry:adverse_events | ||||
| A2 | events | 0 / 28 | not stated; safety; registry:adverse_events |
Serious adverse events (2 lines; O25)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| A1 | events | 0 / 28 | not stated; safety; registry:adverse_events | ||||
| A2 | events | 0 / 28 | not stated; safety; registry:adverse_events |
Nausea (2 lines; O27A)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| A1 | events | 7 / 18 | not stated; other; R0022856:Results | ||||
| A2 | events | 7 / 18 | not stated; other; R0022856:Results |
Death by suicide (2 lines; O35B)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| A1 | events | 0 / 28 | not stated; safety; registry:adverse_events | ||||
| A2 | events | 0 / 28 | not stated; safety; registry:adverse_events |